Alaunos Therapeutics (TCRT) Stock: Buy, Sell, or Hold?
TCRT - Alaunos Therapeutics, Inc. Common Stock
$0.79
-0.05 (-5.69%)
▼
5d:
-14.09%
30d:
-49.33%
90d:
-61.44%
WAIT
LOW Confidence
Analysis Updated: Oct 7, 2026 12:00 AM ET
Earnings: Nov 13, 2026
Get Alerted When TCRT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: TCRT is down 14.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: TCRT is down 14.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: TCRT is currently trading at $0.79, which is considered oversold relative to its 30-day fair value range of $0.94 to $1.58.
Technical Outlook: Technically, TCRT is in a strong downtrend. Immediate support is located at $0.72, while resistance sits at $1.16. Short-term momentum is weak, with the stock down 5.7% recently.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $1.75 (+108.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TCRT is in a strong downtrend. Immediate support is located at $0.72, while resistance sits at $1.16. Short-term momentum is weak, with the stock down 5.7% recently.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $1.75 (+108.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.94 -
$1.58
Company Quality Score
50/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
72.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (55/100)
- BEARISH: Downward momentum (-5.7%)
- BULLISH: Trading 108.8% below Wall St target ($1.75)
- WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.94 -
$1.58
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.72
Resistance Level
$1.16
Current Trend
Strong Downtrend
Technical data as of
Oct 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
18.48
Wall Street Target
$1.75
(+108.8%)
Revenue Growth (YoY)
-25.0%
Share & Embed Analysis
Last updated: October 08, 2026 1:11 PM ET
Data refreshes hourly during market hours. Next update: 2:11 PM
Data refreshes hourly during market hours. Next update: 2:11 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TCRT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$571 | 56 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
29 analysts |
$371 | 54 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 52 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
20 analysts |
$307 | 65 BUY |
|
PVLA
Palvella Therapeutics, I… |
STRONG BUY
15 analysts |
$231 | 52 HOLD |
